Market Research Logo

Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2016

Table of Contents
List of Tables
List of Figures
Teva Pharmaceutical Industries Limited Snapshot
Teva Pharmaceutical Industries Limited Overview
Key Information
Key Facts
Teva Pharmaceutical Industries Limited - Research and Development Overview
Key Therapeutic Areas
Teva Pharmaceutical Industries Limited - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
Teva Pharmaceutical Industries Limited - Pipeline Products Glance
Teva Pharmaceutical Industries Limited - Late Stage Pipeline Products
Teva Pharmaceutical Industries Limited - Clinical Stage Pipeline Products
Teva Pharmaceutical Industries Limited - Early Stage Pipeline Products
Teva Pharmaceutical Industries Limited - Unknown Stage Pipeline Products
Teva Pharmaceutical Industries Limited - Drug Profiles
(fluticasone propionate + salmeterol xinafoate)
deutetrabenazine ER
hydrocodone bitartrate ER
laquinimod sodium
reslizumab
omacetaxine mepesuccinate
(acetaminophen + hydrocodone bitartarate) IR
armodafinil
beclomethasone dipropionate
bendamustine hydrochloride
fluticasone propionate
rasagiline mesylate
TEV-48125
funapide
pridopidine hydrochloride
TV-1380
(acetaminophen + oxycodone hydrochloride) IR
(fluticasone propionate + salmeterol xinafoate) MDI
CEP-37440
glatiramer acetate
SD-560
TEV-48107
TEV-90110
TEV-90111
TEV-90112
TEV-90113
TV-44664
atropine sulfate
CEP-11981
CEP-28122
CEP-33779
Drug for Undisclosed Indication
NIB-2
NP-201
NP-202
Recombinant Protein to Inhibit IL-17A for Psoriasis
Recombinant Protein to Target CD38 for Multiple Myeloma
SD-1077
Small Molecule 2 to Antagonize 5-HT6 for CNS Disorders
Small Molecule to Antagonize NMDA Receptor for Undisclosed Indication
Small Molecule to Inhibit CGRP for Migraine
Small Molecules to Inhibit DAT for Sleep Disorders
(acetaminophen + immediate release opioid 1)
(acetaminophen + immediate release opioid 2)
AD-3
AD-4
Fixed Dose Combination 3 for HIV
Fixed Dose Combination 4 for HIV
Small Molecule 1 to Antagonize 5-HT6 Receptor for CNS Disorders
Small Molecule to Inhibit PARP-1
Drug for Dependence
Drug for Parkinson's Disease
risperidone LAI
Teva Pharmaceutical Industries Limited - Pipeline Analysis
Teva Pharmaceutical Industries Limited - Pipeline Products by Target
Teva Pharmaceutical Industries Limited - Pipeline Products by Route of Administration
Teva Pharmaceutical Industries Limited - Pipeline Products by Molecule Type
Teva Pharmaceutical Industries Limited - Pipeline Products by Mechanism of Action
Teva Pharmaceutical Industries Limited - Recent Pipeline Updates
Teva Pharmaceutical Industries Limited - Dormant Projects
Teva Pharmaceutical Industries Limited - Discontinued Pipeline Products
Teva Pharmaceutical Industries Limited - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Teva Pharmaceutical Industries Limited - Company Statement
Teva Pharmaceutical Industries Limited - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 1
List of Tables
Teva Pharmaceutical Industries Limited, Key Information
Teva Pharmaceutical Industries Limited, Key Facts
Teva Pharmaceutical Industries Limited - Pipeline by Indication, 2016
Teva Pharmaceutical Industries Limited - Pipeline by Stage of Development, 2016
Teva Pharmaceutical Industries Limited - Monotherapy Products in Pipeline, 2016
Teva Pharmaceutical Industries Limited - Combination Treatment Modalities in Pipeline, 2016
Teva Pharmaceutical Industries Limited - Partnered Products in Pipeline, 2016
Teva Pharmaceutical Industries Limited - Partnered Products/ Combination Treatment Modalities, 2016
Teva Pharmaceutical Industries Limited - Out-Licensed Products in Pipeline, 2016
Teva Pharmaceutical Industries Limited - Out-Licensed Products/ Combination Treatment Modalities, 2016
Teva Pharmaceutical Industries Limited - Pre-Registration, 2016
Teva Pharmaceutical Industries Limited - Filing rejected/Withdrawn, 2016
Teva Pharmaceutical Industries Limited - Phase III, 2016
Teva Pharmaceutical Industries Limited - Phase II, 2016
Teva Pharmaceutical Industries Limited - Phase I, 2016
Teva Pharmaceutical Industries Limited - Preclinical, 2016
Teva Pharmaceutical Industries Limited - Discovery, 2016
Teva Pharmaceutical Industries Limited - Unknown, 2016
Teva Pharmaceutical Industries Limited - Pipeline by Target, 2016
Teva Pharmaceutical Industries Limited - Pipeline by Route of Administration, 2016
Teva Pharmaceutical Industries Limited - Pipeline by Molecule Type, 2016
Teva Pharmaceutical Industries Limited - Pipeline Products by Mechanism of Action, 2016
Teva Pharmaceutical Industries Limited - Recent Pipeline Updates, 2016
Teva Pharmaceutical Industries Limited - Dormant Developmental Projects,2016
Teva Pharmaceutical Industries Limited - Discontinued Pipeline Products, 2016
Teva Pharmaceutical Industries Limited, Other Locations
Teva Pharmaceutical Industries Limited, Subsidiaries
List of Figures
Teva Pharmaceutical Industries Limited - Pipeline by Top 10 Indication, 2016
Teva Pharmaceutical Industries Limited - Pipeline by Stage of Development, 2016
Teva Pharmaceutical Industries Limited - Monotherapy Products in Pipeline, 2016
Teva Pharmaceutical Industries Limited - Combination Treatment Modalities in Pipeline, 2016
Teva Pharmaceutical Industries Limited - Partnered Products in Pipeline, 2016
Teva Pharmaceutical Industries Limited - Out-Licensed Products in Pipeline, 2016
Teva Pharmaceutical Industries Limited - Pipeline by Top 10 Target, 2016
Teva Pharmaceutical Industries Limited - Pipeline by Route of Administration, 2016
Teva Pharmaceutical Industries Limited - Pipeline by Molecule Type, 2016
Teva Pharmaceutical Industries Limited - Pipeline Products by Top 10 Mechanism of Action, 2016

Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2016’, provides an overview of the Teva Pharmaceutical Industries Limited’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Teva Pharmaceutical Industries Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Teva Pharmaceutical Industries Limited
The report provides overview of Teva Pharmaceutical Industries Limited including its business description, key facts, and locations and subsidiaries
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report assesses Teva Pharmaceutical Industries Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report features Teva Pharmaceutical Industries Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Teva Pharmaceutical Industries Limited’s strategic position with total access to detailed information on its product pipeline
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Teva Pharmaceutical Industries Limited
Identify potential new clients or partners in the target demographic
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Teva Pharmaceutical Industries Limited’s pipeline depth and focus of pipeline therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;